Format

Send to

Choose Destination
Health Aff (Millwood). 2006 Sep-Oct;25(5):1249-59.

Translating epoetin research into practice: the role of government and the use of scientific evidence.

Author information

1
Medical Technology and Practice Patterns Institute Inc., Bethesda, Maryland, USA. dcott@mtppi.org

Abstract

Spending for epoetin is Medicare's single largest drug expenditure. We chronicle the evolution of epoetin policy based on a lack of well-designed post-Food and Drug Administration approval studies demonstrating clinical benefit; congressional/federal agency reliance on clinical practice guidelines that might have misinterpreted evidence supporting causality; and the premature translation of research into practice and policy. Were the right choices made? Epoetin showcases the risk and benefit conundrum created when evidentiary standards are relaxed. Our review concludes with broad-based policy recommendations for the newly implemented Medicare Part D program.

PMID:
16966720
DOI:
10.1377/hlthaff.25.5.1249
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center